Sweeteners

Added sugar accelerates biological aging; "diet" sweeteners are not biologically inert; sugar alcohols carry a real cardiovascular signal. The cleanest replacements for routine use are monk fruit and allulose, with small amounts of real honey as a moderate occasional option.

For most healthy adults, the dominant lever is removing the largest sources of free sugar — sugar-sweetened beverages first — rather than swapping them for engineered substitutes. Most non-nutritive sweeteners are better than the full-sugar versions they replace but worse than water, coffee, or unsweetened tea over a lifetime.

What the evidence says

Strong:

Sugar-sweetened beverages raise CVD, type 2 diabetes, and all-cause mortality in a dose-response pattern. See foods to limit or avoid.
Added sugar at typical Western intakes (~60 g/day vs. the FDA's <50 g/day recommendation) accelerates epigenetic age measured by second-generation clocks (GrimAge2, DunedinPACE).

Moderate:

Non-nutritive sweeteners (aspartame, sucralose, saccharin, ace-K) do not produce sustained weight loss in long-term trials and associate with stroke and dementia in cohort data (^[1]; WHO 2023 conditional recommendation against use for weight control).
Erythritol and xylitol — the two dominant "keto" sugar alcohols — associate with major adverse cardiovascular events at the population level and enhance platelet reactivity in mechanistic experiments (^[2]; ^[3]).
Allulose lowers postprandial glucose and insulin in human RCTs by stimulating endogenous GLP-1 release.
Honey (raw, ~40 g/day for 8 weeks) modestly improves fasting glucose, LDL-C, and HDL-C in pooled RCTs.

Weak / preliminary:

Intergenerational microbiome and gene-expression effects of sweeteners — mouse data only.
Allulose, monk fruit, and honey-polyphenol activation of AMPK / SIRT1 longevity pathways — preclinical.
Manuka honey methyl syringate as a systemic anti-inflammatory longevity therapeutic — in vitro and animal.

Caution:

Erythritol and xylitol used as routine bulk sweeteners in adults with established cardiovascular disease, prior stroke, atrial fibrillation, or otherwise elevated thrombotic risk.

Added sugar accelerates biological aging

The clearest single finding to emerge in the last few years is that added free sugars accelerate the epigenetic clocks now used as the standard biomarker of biological age. A 2024 ^[4] of midlife Black and White women in the NIMHD Social Epigenomics cohort found a dose-response association between daily added-sugar intake and acceleration of the GrimAge2 and DunedinPACE clocks. Mean intake was ~61 g/day, above the FDA's 50 g/day ceiling.

The mechanism is not exotic. Chronically elevated postprandial glucose and fructose drive de novo lipogenesis, advanced glycation end-products, and low-grade inflammation, all of which alter DNA-methylation patterns toward the senescent profile the clocks read off. NHANES analyses of leukocyte telomere length point in the same direction: regular sugar-sweetened soda consumption associates with shorter telomeres in otherwise-healthy adults (^[5]).

The headline number from the JAMA Network Open paper — "every gram of added sugar nudges the clock forward" — is true at the population level but should be read as a monotonic dose-response, not a per-gram action threshold. For practical purposes, the WHO/AHA targets of <25 g/day added sugar (women) or <10% of total calories capture most of the benefit available from the lever.

This is the strongest evidence-based reason to remove sugar-sweetened beverages first: they are the largest single source of added sugar in most diets, and the cohort data linking them to mortality is older and more consistent than any data on the substitutes.

Non-nutritive sweeteners are not inert

Aspartame, sucralose, saccharin, and acesulfame-K were originally licensed on the assumption that anything that didn't deliver calories couldn't matter metabolically. That assumption has not held up.

The WHO 2023 guideline. A systematic review found no long-term body-fat benefit from non-sugar sweeteners and signals of increased risk for type 2 diabetes, cardiovascular disease, and all-cause mortality with habitual use. The certainty rating in the underlying evidence is low — the conditional recommendation against use reflects weighing potential harm against the absence of demonstrated benefit, not strong direct evidence of damage (^[6]).

Cohort signals. The Framingham Offspring Study found daily artificially-sweetened soft-drink intake associated with roughly threefold higher rates of incident ischemic stroke and Alzheimer's dementia over a decade of follow-up (^[7]). The 2024 ELSA-Brasil cohort (n=12,772, ~8 years follow-up) reported that the highest intake of low- and no-calorie sweeteners associated with measurably faster declines in global cognition, memory, and verbal fluency — equivalent to ~1.3 years of accelerated cognitive aging across the study period (^[8]). Both are observational; reverse causality (people switching to diet drinks because of pre-existing metabolic disease) is plausible and partially controllable but not eliminable.

Microbiome and glucose tolerance. A 2022 Cell RCT (Suez et al.) gave non-diabetic adults daily doses of saccharin or sucralose for two weeks and found measurable shifts in gut-microbiome composition and glycemic response — with the size of the effect varying by individual baseline microbiome. This is the cleanest causal evidence that NNS are biologically active, but the long-term clinical significance is unclear.

Intergenerational data. A 2026 Frontiers in Nutrition mouse study reported that parental sucralose and stevia consumption produced microbiome and gene-expression changes in offspring out to F2. Interesting but mouse-only; transgenerational extrapolation to humans is speculative, and rodent coprophagy complicates microbiome-mediated inheritance specifically.

Practical reading. Non-nutritive sweeteners are better than the sugar versions they replace if the alternative is a daily SSB, and they're useful as a transitional tool when tapering off sugar. They are not a long-term default. Water, coffee, tea, and sparkling water are.

Sugar alcohols: the polyol cardiovascular signal

The most consequential dietary-sweetener finding of the last several years concerns erythritol and xylitol — the two polyols that dominate "keto," "diabetic," and sugar-free product categories.

Erythritol. A 2023 Nature Medicine paper from the Cleveland Clinic group analyzed a discovery cohort plus US (n=2,149) and European (n=833) replication cohorts and found that plasma erythritol in the highest quartile predicted three-year MACE (composite of cardiovascular death, MI, and stroke) with adjusted hazard ratios around 2.0 (^[9]). Mechanistically, the same group showed erythritol enhances platelet reactivity at physiologically achievable plasma concentrations and that a single sweetener-typical dose (~30 g) raises plasma levels above the platelet-activation threshold for >48 hours.

One important caveat the headlines often miss. Circulating erythritol is partly endogenous: the body produces it from glucose via the pentose phosphate pathway, and production rises in metabolic stress. The cohort data therefore mixes a biomarker effect (erythritol as a marker of underlying cardiometabolic disease) with a direct-toxicity effect. The mechanistic platelet work is what makes the dietary-intake interpretation plausible — and is the load-bearing piece for the recommendation, not the hazard ratio alone.

Xylitol. A 2024 European Heart Journal paper from the same group ran the same analysis and found ~1.6× higher three-year MACE risk in the highest tertile of plasma xylitol, with mechanistic platelet-reactivity data again confirming biological plausibility (^[10]).

Sorbitol is less studied, but the same metabolic family. Maltitol and isomalt have not generated comparable signals.

Practical: treat erythritol- and xylitol-sweetened products (keto baking goods, sugar-free candies, low-carb protein bars) as occasional, not staples — particularly for adults with established cardiovascular disease, prior stroke, atrial fibrillation, or those on antiplatelet therapy. The xylitol gum used in dentistry is small-dose and doesn't reach the plasma levels that drive the platelet effect.

Stevia and monk fruit

Both are plant-derived, zero-calorie high-intensity sweeteners. They are reasonable replacements for synthetic NNS when sweetness is wanted without calories, with monk fruit currently the cleaner profile.

Stevia (steviol glycosides, ~200–300× sweeter than sucrose). In short-term human studies, no consistent harm signal on glucose, blood pressure, or weight; some animal data suggests mild antioxidant and anti-inflammatory effects. Two qualifications: it has been shown to interfere with bacterial quorum sensing, raising the question of microbiome effects at high chronic intake; and the 2026 Frontiers in Nutrition mouse study (cited above) included stevia and found milder but nonzero intergenerational signals. For the average adult, stevia in modest amounts is fine; it should not be assumed perfectly inert.

Monk fruit (mogrosides, ~150–250× sweeter than sucrose). Mogrosides pass intact through the upper GI tract; colonic bacteria cleave the glucose moiety and use the rest as a substrate, with possible prebiotic effects. In vitro and animal data suggest mogroside V has antioxidant activity. There is no human cardiovascular, microbiome, or cognitive harm signal of meaningful size to date — though the human evidence base is thinner than for sucralose or aspartame, and "no signal yet" is not the same as "demonstrated safe at high lifetime intake."

For the healthy adult choosing between high-intensity sweeteners, monk fruit is currently the most defensible default.

Rare sugars: allulose and tagatose

Rare sugars are naturally occurring monosaccharides whose structural variations change how the human body handles them. The two with meaningful human data are D-allulose and D-tagatose. Both are technically caloric (~0.4 kcal/g for allulose, ~1.5 kcal/g for tagatose) but mostly not metabolized for energy.

Allulose. Roughly 70% is absorbed in the small intestine and excreted unchanged in urine; the remaining 30% reaches the colon and resists fermentation. In human RCTs, pre-meal allulose lowers postprandial glucose and insulin, particularly with carbohydrate-heavy meals. The mechanism is endogenous GLP-1 release: allulose triggers GLP-1 secretion in the gut, activating vagal afferents that signal satiety to the brainstem and hypothalamus (^[11]). In animal models, GLP-1-receptor knockout or vagotomy abolishes the anti-obesity and glucose-lowering effects, confirming the GLP-1–vagal axis is doing the work.

A practical caveat: allulose is not a substitute for prescription GLP-1 receptor agonists. The endogenous GLP-1 signal it produces is small in absolute terms compared to a semaglutide dose. Frame it as a useful sugar substitute that doesn't raise blood glucose, not as a "natural Ozempic."

The longevity-pathway claims sometimes attached to allulose — AMPK and SIRT1 activation in adipocytes, C. elegans lifespan extension — are real preclinical findings but should not be over-interpreted; they are not a basis for human longevity recommendations.

Tagatose has FDA GRAS status and a low glycemic index. Small trials show modest HbA1c improvements and lipid changes; no significant safety signals.

Practical. For an adult who wants a sugar substitute that bakes and tastes close to sucrose without raising glucose, allulose is currently the best-evidenced option. The gating factors are cost and availability; GI tolerability (loose stools, gas) is the most common limiting issue at >0.5 g/kg per single dose.

Honey

Honey is ~80% simple sugars by mass, but the matrix matters. Raw, unfiltered honey contains over 200 bioactive compounds — flavonoids, phenolic acids, glucose oxidase, catalase. Pasteurized, ultrafiltered supermarket honey has most of these stripped and behaves nutritionally closer to high-fructose corn syrup.

A 2023 University of Toronto systematic review and meta-analysis pooled 18 RCTs (>1,000 participants, median dose ~40 g/day for ~8 weeks) and found honey consumption associated with modest reductions in fasting glucose, ALT, total and LDL cholesterol, and triglycerides, alongside small HDL-C increases — counterintuitive given the sugar content, attributed to the polyphenol matrix. Effect sizes are clinically modest and the trials are mostly short.

Manuka honey (high-methylglyoxal honey from Leptospermum scoparium) has well-established topical antibacterial activity. The systemic anti-inflammatory and SIRT1-activation claims are based on in vitro neutrophil work and small animal studies — interesting, not load-bearing.

Practical reading. A tablespoon (~20 g) of raw honey in tea or yogurt as an occasional sweetener is fine and probably modestly better than refined sugar in equivalent amount, because of the polyphenol content. It is still ~80% sugar; volume matters more than provenance.

Practical guidance

Remove sugar-sweetened beverages first. This is the largest dietary lever for added-sugar reduction in most diets, and the SSB-specific harm data is the strongest in the entire sweetener literature.
Default beverages: water, coffee, tea, sparkling water. Unsweetened. This is a more impactful change than choosing between non-nutritive alternatives.
Hold added sugar to <25 g/day (women) / <36 g/day (men) / <10% of calories. Most of the biological-aging signal is at higher intakes.
For zero-calorie sweetness when wanted: monk fruit > stevia > NNS. Use as a tool, not a daily default.
For sugar substitutes in baking: allulose if cost permits; otherwise small amounts of regular sugar in an otherwise Mediterranean-pattern diet.
Avoid erythritol and xylitol as routine bulk sweeteners if you have established cardiovascular disease, atrial fibrillation, prior stroke, or are on antiplatelet therapy. The xylitol gum used dentally is too small-dose to matter.
Honey: occasional, raw if possible, ~1 tablespoon. Treat as a sugar with extras, not a health food.
Don't switch to diet sodas as a long-term strategy — short-term taper from full-sugar SSBs is a reasonable use, but the multi-year cohort data on cognitive and vascular endpoints is worth taking seriously.

What's overrated

"Allulose is a longevity mimetic." Based on AMPK/SIRT1 activation in adipocytes and C. elegans lifespan extension. Real preclinically; not a human longevity claim.
"Manuka honey is anti-aging." In vitro neutrophil and SIRT1 work; useful for wound care, not a systemic intervention.
"Stevia is biologically inert because it's natural." It alters bacterial quorum sensing and showed mild intergenerational signals in mice. Probably fine; not zero.
"Diet sodas are safe replacements." Better than SSBs in the short term; the long-term cohort data on stroke and dementia is hard to dismiss.
Transgenerational sweetener inheritance from mouse studies as a near-term human concern. Worth tracking; not currently a basis for recommendations.